Medical device and MedTech insights, news, tips and more
HeartBeam Announces Acquisition of LIVMOR Assets
March 15, 2023
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition extends HeartBeam’s reach in remote monitoring and detection with full ownership of an existing cutting-edge FDA-cleared product.
Founded in 2016, LIVMOR developed the Halo+™ Atrial Fibrillation (AF) Detection System, the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. The Halo system provides continuous monitoring of pulse rhythms for the detection of AF on-demand during the day and automatically overnight. LIVMOR’s technology was commercially deployed within the VA Healthcare System in Dallas, Texas.
In February 2022, HeartBeam partnered with LIVMOR to build a HeartBeam-branded version of LIVMOR’s FDA-cleared Halo cloud-based software platform to connect physicians and patients. Utilizing the Halo cloud-based platform allowed HeartBeam to meet its schedule for FDA submission of the HeartBeam AIMI™ software for acute care settings that provides a 3D vector electrogram (VECG) comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack.
Under the terms of the acquisition agreement, HeartBeam purchased LIVMOR’s intellectual property for an undisclosed amount, including 3 issued United States patents, LIVMOR technology, including the Halo AF Detection System, LIVMORs business contracts and relationships as well as all Samsung watch and tablet inventory. Additionally, HeartBeam hired LIVMOR’s key technical employees.
“We’re very pleased to complete this acquisition as it is a natural fit and extension of our successful partnership with LIVMOR and our complementary goals to dramatically improve patient outcomes and to significantly reduce healthcare system costs,” said Branislav Vajdic, Ph.D., HeartBeam CEO and Founder. “The fact that these intellectual property and product assets were developed by the technical team that is now part of HeartBeam means that we will be able to integrate the Halo cloud-based software platform with our AIMGO solution in an efficient and cost-effective manner,” concluded Vajdic.
Founded in 2016, LIVMOR is a digital health solutions company whose mission is to assist physicians and medical professionals in addressing the global chronic disease epidemic by providing a patient-engaging remote monitoring system of critical physiological biomarkers. LIVMOR’s goals are to dramatically improve patient outcomes and to significantly reduce healthcare system costs with better quality data for diagnosis and treatment of chronic diseases. For more information, visit www.livmor.com.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
See Full Press Release at the Source: HeartBeam Announces Acquisition of LIVMOR Assets
Press Release by: HeartBeam
Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.
We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.
Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.